Trial reportScientific reports2024
Quantitative comparison of automated OCT and conventional FAF-based geographic atrophy measurements in the phase 3 OAKS/DERBY trials.
Trial report in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Longitudinal Prediction of Retinal Sensitivity Based on Disease Progression Quantified From Optical Coherence Tomography in Geographic Atrophy.Investigative ophthalmology & visual science · 2026Trial
- Deep Learning-Based Automated Segmentation and Quantification of the Ellipsoid Zone and the RPE-Bruch's Membrane Complex in Healthy Subjects and in Geographic Atrophy.Diagnostics (Basel, Switzerland) · 2026Article
- Histologic Photoreceptor and Retinal Pigment Epithelium Degeneration in an Eye With Clinically Documented Geographic Atrophy of AMD.Investigative ophthalmology & visual science · 2026Article
- Automated OCT-tailored and same-visit biomarker-targeted microperimetry in geographic atrophy.Scientific reports · 2026Article
- Comparing Interactive Machine Learning and Unassisted Segmentation of Geographic Atrophy From Fundus Autofluorescence.Translational vision science & technology · 2026Article
- CLEAR report 1: a scoping review and meta-analysis for definitions, imaging metrics, and functional correlates of photoreceptor integrity in AMD.Frontiers in medicine · 2026Review
- Patient-level forecasting of geographic atrophy with a biologically grounded Gompertz model.medRxiv : the preprint server for health sciences · 2025Article
- Imaging of Geographic Atrophy: A Practical Approach.Ophthalmology and therapy · 2025Article
- Longitudinal Comparison of Geographic Atrophy Enlargement Using Manual, Semiautomated, and Deep Learning Approaches.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the approval of the first two substances for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a standardized monitoring of patients treated with complement inhibitors in clinical practice is needed. Optical coherence tomography (OCT) provides high-resolution access to the retinal pigment epithelium (RPE) and neurosensory layers, such as the ellipsoid zone (EZ), which further enhances the understanding of disease progression and therapeutic effects in GA compared to conventional fundus autofluorescence (FAF). In addition, artificial intelligence-based methodology allows the identification and quantification of GA-related pathology on OCT in an objective and standardized manner. The purpose of this study was to comprehensively evaluate automated OCT monitoring for GA compared to reading center-based manual FAF measurements in the largest successful phase 3 clinical trial data of complement inhibitor therapy to date. Automated OCT analysis of RPE loss showed a high and consistent correlation to manual GA measurements on conventional FAF. EZ loss on OCT was generally larger than areas of RPE loss, supporting the hypothesis that EZ loss exceeds underlying RPE loss as a fundamental pathophysiology in GA progression. Automated OCT analysis is well suited to monitor disease progression in GA patients treated in clinical practice and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.